Protein synthesis inhibition blocks the induction of mossy fiber long-term potentiation in vivo.
Protein synthesis inhibitors block the maintenance of NMDA receptor-dependent long-term potentiation (LTP) both in vivo and in vitro. Protein synthesis inhibitors block mossy fiber(MF) LTP maintenance in vitro, but little is known about the effect of protein synthesis inhibitors on either induction or maintenance in MF-LTP in vivo. Here we study the role of protein synthesis in the induction of long-term potentiation at the mossy fiber-CA3 hippocampal synapse in vivo in anesthetized rats. The protein synthesis inhibitor anisomycin was administered at different doses (0.04, 10, or 40 nmol) into area CA3 15 min before delivering high-frequency stimulation (two times at 100 Hz, 1 sec). Anisomycin blocked MF-LTP induction in a dose-dependent manner; both 40 and 10 nmol blocked MF-LTP induction, but a lower dose of 0.04 nmol was without effect. The inhibitory effect of anisomycin on protein synthesis was determined by measuring the incorporation of [(35)S]methionine into the newly synthesized proteins. Percentages of protein synthesis inhibition were determined by comparing [(35)S] incorporation of anisomycin-treated samples with vehicle controls. Doses of 0.04, 10, or 40 nmol of anisomycin produced 21, 82, or 83% inhibition of [(35)S]methionine incorporation, respectively. The effect of anisomycin was verified using a single dose of the protein synthesis inhibitor cycloheximide (40 nmol). Cycloheximide also blocked MF-LTP induction. These results suggest that protein synthesis plays an important role in the induction of mossy fiber long-term potentiation in vivo.
Barea-Rodríguez
E J
EJ
University of Texas at San Antonio, Division of Life Sciences, San Antonio, Texas 78249, USA. ebarea@utsa.edu
Rivera
D T
DT
Jaffe
D B
DB
Martinez
J L
JL
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000841:Anisomycin / Q000008:administration & dosage*; D002118:Calcium / Q000378:metabolism; D003513:Cycloheximide / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D005456:Fluorescent Dyes; D016257:Fura-2; D066298:In Vitro Techniques; D007424:Intracellular Fluid / Q000378:metabolism; D017774:Long-Term Potentiation / Q000187:drug effects*; D008297:Male; D008715:Methionine / Q000378:metabolism; D008845:Microinjections; D019599:Mossy Fibers, Hippocampal / Q000187:drug effects* / Q000502:physiology; D018408:Patch-Clamp Techniques; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley
D005456:Fluorescent Dyes; D011500:Protein Synthesis Inhibitors; D000841:Anisomycin; D003513:Cycloheximide; D008715:Methionine; D002118:Calcium; D016257:Fura-2